Trial Profile
A randomized, double-blind, placebo and reference controlled, multiple ascending dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of Memogain administered by intranasal application to healthy elderly subjects.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 13 Oct 2021
Price :
$35
*
At a glance
- Drugs Benzgalantamine (Primary) ; Galantamine
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors AlphaCognition
- 07 Oct 2021 According to an AlphaCognition media release, top-line data read-out from BABE study is scheduled for late Q1 2022.
- 24 Mar 2018 Status changed to active, no longer recruiting.
- 24 Mar 2018 Primary endpoint (Adaptive tracking performance (22 mg GLN-1062 vs Placebo)) has been met as per the results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.